Syros Pharmaceuticals, Inc. (0S9.F)
| Previous Close | 0.8052 |
| Open | 0.8636 |
| Bid | 0.7394 x 0 |
| Ask | 0.7422 x 0 |
| Day's Range | 0.7426 - 0.8636 |
| 52 Week Range | 0.7426 - 5.8500 |
| Volume | |
| Avg. Volume | 161 |
| Market Cap | 46.002M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
CAMBRIDGE, Mass., May 16, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.
- Business Wire
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
CAMBRIDGE, Mass., May 09, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update.
- Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 29, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 136,750 shares of Syros common stock to six newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
